SEC Comment Letter 0000000000-23-011637 to Pacira BioSciences, Inc. (PCRX) (CIK 0001396814) (PCRX)
Pacira BioSciences, Inc. (PCRX) (CIK 0001396814)
Date: Oct. 24, 2023 · CIK: 0001396814 · Accession: 0000000000-23-011637
AI Filing Summary & Sentiment
File numbers found in text: 001-35060
Letter
United States securities and exchange commission logo October 24, 2023 Charles Reinhart, III Chief Financial Officer Pacira BioSciences, Inc. 5401 West Kennedy Boulevard, Suite 890 Tampa, Florida 33609 Re:Pacira BioSciences, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 28, 2023 File No. 001-35060 Dear Charles Reinhart: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
October 24, 2023
Charles Reinhart, III
Chief Financial Officer
Pacira BioSciences, Inc.
5401 West Kennedy Boulevard, Suite 890
Tampa, Florida 33609
Re:Pacira BioSciences, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed February 28, 2023
File No. 001-35060
Dear Charles Reinhart:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences